ArticleTherapeutic advances in neurological disorders2025

Evaluating natalizumab first-line and later-line use in multiple sclerosis: a US claims database analysis.

Robin L Avila et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.